Commission Regulation (EU) 2020/878



### **Emamectin Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
4.2	28.09.2024	24922-00029	Date of first issue: 23.10.2014

### **SECTION 1:** Identification of the substance/mixture and of the company/undertaking

1.1	Product identifier		
	Trade name	:	Emamectin Formulation
1.2	Relevant identified uses of the	ne s	ubstance or mixture and uses advised against
	Use of the Sub- stance/Mixture	:	Veterinary product
	Recommended restrictions on use	:	Not applicable
1.3	Details of the supplier of the	saf	ety data sheet
1.3	Details of the supplier of the Company	saf :	MSD
1.3		saf :	MSD Kilsheelan
1.3		saf :	MSD
1.3		:	MSD Kilsheelan
1.3	Company	:	MSD Kilsheelan Clonmel Tipperary, IE

### 1.4 Emergency telephone number

1-908-423-6000

### **SECTION 2: Hazards identification**

### 2.1 Classification of the substance or mixture

### Classification (REGULATION (EC) No 1272/2008)

Short-term (acute) aquatic hazard, Cate-<br/>gory 1H400: Very toxic to aquatic life.Long-term (chronic) aquatic hazard, Cat-<br/>egory 1H410: Very toxic to aquatic life with long lasting<br/>effects.

### 2.2 Label elements

### Labelling (REGULATION (EC) No 1272/2008)

Hazard pictograms	:	¥2	•
Signal word	:	Warning	
Hazard statements	:	H410	Very toxic to aquatic life with long lasting effects.

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



### **Emamectin Formulation**

Version 4.2	Revision Date: 28.09.2024		DS Number: 4922-00029	Date of last issue: 06.04.2024 Date of first issue: 23.10.2014
Preca	utionary statements	:	Prevention P273	: Avoid release to the environment.
			Response: P391	Collect spillage.

### 2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

Ecological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Toxicological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.


Dust contact with the eyes can lead to mechanical irritation. Contact with dust can cause mechanical irritation or drying of the skin. May form explosive dust-air mixture during processing, handling or other means.

### **SECTION 3: Composition/information on ingredients**

### 3.2 Mixtures

### Components

Chemical name	CAS-No. EC-No. Index-No. Registration number	Classification	Concentration (% w/w)
Emamectin	137512-74-4	Acute Tox. 3; H301 Acute Tox. 3; H331 Eye Dam. 1; H318 STOT SE 1; H370 (Peripheral nervous system, Central nervous system) STOT RE 1; H372 (Peripheral nervous system, Central nervous system) Aquatic Acute 1; H400 Aquatic Chronic 1; H410 M-Factor (Acute aquatic toxicity): 10,000	>= 0.1 - < 0.25





# **Emamectin Formulation**

Version 4.2	Revision Date: 28.09.2024	SDS Number: 24922-00029	Date of last issue: 06.04.2024 Date of first issue: 23.10.2014
			M-Factor (Chronic aquatic toxicity): 10,000
			Acute toxicity esti- mate
			Acute oral toxicity: 100 mg/kg Acute inhalation tox- icity (dust/mist): 0.5 mg/l

For explanation of abbreviations see section 16.

### **SECTION 4: First aid measures**

### 4.1 Description of first aid measures

Gen	eral advice	:	In the case of accident or if you feel unwell, seek medical ad- vice immediately. When symptoms persist or in all cases of doubt seek medical advice.
Prote	ection of first-aiders	:	No special precautions are necessary for first aid responders.
lf inh	aled	:	If inhaled, remove to fresh air. Get medical attention if symptoms occur.
In ca	se of skin contact	:	Wash with water and soap. Get medical attention if symptoms occur.
In ca	se of eye contact	:	If in eyes, rinse well with water. Get medical attention if irritation develops and persists.
lf sw	allowed	:	If swallowed, DO NOT induce vomiting. Get medical attention if symptoms occur. Rinse mouth thoroughly with water.
4.2 Most	important symptoms and	d e	ffects, both acute and delayed
Risk	S	:	Contact with dust can cause mechanical irritation or drying of the skin. Dust contact with the eyes can lead to mechanical irritation.

### 4.3 Indication of any immediate medical attention and special treatment needed

Treatment	:	Treat symptomatically and supportively.
-----------	---	---



### **Emamectin Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
4.2	28.09.2024	24922-00029	Date of first issue: 23.10.2014

### **SECTION 5: Firefighting measures**

### 5.1 Extinguishing media

Suitable extinguishing media	:	Water spray Alcohol-resistant foam Carbon dioxide (CO2) Dry chemical
Unsuitable extinguishing media	:	None known.

### 5.2 Special hazards arising from the substance or mixture

5.2 Special hazards arising from	the	e substance or mixture
Specific hazards during fire- fighting	:	Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard. Exposure to combustion products may be a hazard to health.
Hazardous combustion prod- ucts	:	Carbon oxides
5.3 Advice for firefighters		
Special protective equipment for firefighters	:	Wear self-contained breathing apparatus for firefighting if nec- essary. Use personal protective equipment.
Specific extinguishing meth- ods	:	Use extinguishing measures that are appropriate to local cir- cumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so.

Evacuate area.

### **SECTION 6: Accidental release measures**

### 6.1 Personal precautions, protective equipment and emergency procedures

Personal precautions	:	Follow safe handling advice (see section 7) and personal pro- tective equipment recommendations (see section 8).
6.2 Environmental precautions		
Environmental precautions	:	Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water.

Local authorities should be advised if significant spillages

# 6.3 Methods and material for containment and cleaning up

Methods for cleaning up	:	Sweep up or vacuum up spillage and collect in suitable con- tainer for disposal.
		Avoid dispersal of dust in the air (i.e., clearing dust surfaces

cannot be contained.

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# **Emamectin Formulation**

Version	Revision Date: 28.09.2024	SDS Number:	Date of last issue: 06.04.2024
4.2		24922-00029	Date of first issue: 23.10.2014
		es, as these m leased into the Local or nation posal of this m employed in th mine which reg Sections 13 an	ed air). should not be allowed to accumulate on surfac- ay form an explosive mixture if they are re- atmosphere in sufficient concentration. al regulations may apply to releases and dis- aterial, as well as those materials and items e cleanup of releases. You will need to deter- gulations are applicable. In 15 of this SDS provide information regarding or national requirements.

### 6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

### **SECTION 7: Handling and storage**

### 7.1 Precautions for safe handling

	9	
Technical measures	:	Static electricity may accumulate and ignite suspended dust causing an explosion. Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.
Local/Total ventilation Advice on safe handling	:	Use only with adequate ventilation. Do not breathe dust. Handle in accordance with good industrial hygiene and safety
		practice, based on the results of the workplace exposure as- sessment
		Minimize dust generation and accumulation. Keep container closed when not in use.
		Keep away from heat and sources of ignition.
		Take precautionary measures against static discharges.
		Take care to prevent spills, waste and minimize release to the environment.
Hygiene measures	:	If exposure to chemical is likely during typical use, provide eye
		flushing systems and safety showers close to the working
		place. When using do not eat, drink or smoke. Wash contami- nated clothing before re-use.
		The effective operation of a facility should include review of engineering controls, proper personal protective equipment,
		appropriate degowning and decontamination procedures,
		industrial hygiene monitoring, medical surveillance and the
		use of administrative controls.
7.2 Conditions for safe storage, i	inc	luding any incompatibilities
Requirements for storage	:	Keep in properly labelled containers. Store in accordance with
areas and containers	•	the particular national regulations.
Advice on common storage		Do not store with the following product types:
	•	Strong oxidizing agents
7.3 Specific end use(s)		
Specific use(s)	:	No data available



### **Emamectin Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
4.2	28.09.2024	24922-00029	Date of first issue: 23.10.2014

### **SECTION 8: Exposure controls/personal protection**

### 8.1 Control parameters

### **Occupational Exposure Limits**

dusts non-specific

4 mg/m3 Value type (Form of exposure): OELV - 8 hrs (TWA) (Respirable dust) Basis: IE OEL

10 mg/m3 Value type (Form of exposure): OELV - 8 hrs (TWA) (inhalable dust) Basis: IE OEL

Components	CAS-No.	Value type (Form of exposure)	Control parameters	Basis		
Starch	9005-25-8	OELV - 8 hrs (TWA) (Respira- ble dust)	4 mg/m3	IE OEL		
		OELV - 8 hrs (TWA) (inhalable dust)	10 mg/m3	IE OEL		
Propylene glycol	57-55-6	OELV - 8 hrs (TWA) (particles)	10 mg/m3	IE OEL		
		OELV - 8 hrs (TWA) (total (va- pour and parti- cles))	150 ppm 470 mg/m3	IE OEL		
Emamectin	137512-74- 4	TWA	15 μg/m3 (OEB 3)	Internal		
	Further information: Skin					
		Wipe limit	150 µg/100 cm2	Internal		

### Derived No Effect Level (DNEL) according to Regulation (EC) No. 1907/2006

Substance name	End Use	Exposure routes	Potential health ef- fects	Value
Propylene glycol	Workers	Inhalation	Long-term local ef- fects	10 mg/m3
	Workers	Inhalation	Long-term systemic effects	168 mg/m3
	Consumers	Inhalation	Long-term local ef- fects	10 mg/m3
	Consumers	Inhalation	Long-term systemic effects	50 mg/m3

### Predicted No Effect Concentration (PNEC) according to Regulation (EC) No. 1907/2006

Substance name	Environmental Compartment	Value
Propylene glycol	Fresh water	260 mg/l

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# **Emamectin Formulation**

Version 4.2	Revision Date: 28.09.2024	SDS Number: 24922-00029	Date of last issue: Date of first issue:	
1		Freshwater -	intermittent	183 mg/l
		Marine water		26 mg/l
		Sewage treat	tment plant	20000 mg/l
		Fresh water	sediment	572 mg/kg dry weight (d.w.)
		Marine sedin	nent	57.2 mg/kg dry weight (d.w.)
		Soil		50 mg/kg dry weight (d.w.)

### 8.2 Exposure controls

### **Engineering measures**

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices).

Minimize open handling.

### Personal protective equipment

Eye/face protection	:	Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.
Hand protection		
Material	:	Chemical-resistant gloves
Remarks Skin and body protection	:	Consider double gloving. Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, dis- posable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentially contaminated clothing.
Respiratory protection Filter type	:	If adequate local exhaust ventilation is not available or expo- sure assessment demonstrates exposures outside the rec- ommended guidelines, use respiratory protection. Equipment should conform to I.S. EN 143 Particulates type (P)

### **SECTION 9: Physical and chemical properties**

#### 9.1 Information on basic physical and chemical properties

Physical state	:	powder
Colour	:	white
Odour	:	No data available

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# **Emamectin Formulation**

Vers 4.2	sion	Revision Date: 28.09.2024		S Number: 022-00029	Date of last issue: 06.04.2024 Date of first issue: 23.10.2014
	Odour <sup>-</sup>	Threshold	:	No data available	
	Melting	point/freezing point	:	No data available	
	Initial b range	oiling point and boiling	:	No data available	
	Flamma	ability (solid, gas)	:	May form explosi dling or other me	ve dust-air mixture during processing, han- ans.
	Flamma	ability (liquids)	:	No data available	
		explosion limit / Upper bility limit	:	No data available	
		explosion limit / Lower bility limit	:	No data available	
	Flash p	oint	:	No data available	
	Auto-ig	nition temperature	:	No data available	•
	Decom	position temperature	:	No data available	•
	рН		:	No data available	
	Viscosi Visc	ty cosity, kinematic	:	No data available	
	Solubili Wat	ty(ies) er solubility	:	soluble	
	Partitio octanol	n coefficient: n- /water	:	No data available	
	Vapour	pressure	:	No data available	•
	Relative	e density	:	No data available	
	Relative	e vapour density	:	No data available	•
		characteristics icle size	:	No data available	
9.2		formation			
	Explosi	ves	:	Not explosive	
	Oxidizir	ng properties	:	The substance or	mixture is not classified as oxidizing.

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



### **Emamectin Formulation**

Version 4.2	Revision Date: 28.09.2024	SDS Number: 24922-00029	Date of last issue: 06.04.2024 Date of first issue: 23.10.2014
Evapo	oration rate	: No data availa	ble
Molecular weight		: No data availa	ble

### **SECTION 10: Stability and reactivity**

### 10.1 Reactivity

Not classified as a reactivity hazard.

### 10.2 Chemical stability

Stable under normal conditions.

### 10.3 Possibility of hazardous reactions

Hazardous reactions	: May form explosive dust-air mixture during processing, han- dling or other means. Can react with strong oxidizing agents.
10.4 Conditions to avoid	
Conditions to avoid	: Heat, flames and sparks. Avoid dust formation.

### 10.5 Incompatible materials

Oxidizing agents

### **10.6 Hazardous decomposition products**

No hazardous decomposition products are known.

### **SECTION 11: Toxicological information**

### 11.1 Information on hazard classes as defined in Regulation (EC) No 1272/2008

Information on likely routes of : Inhalation exposure Skin contact Ingestion Eye contact

### Acute toxicity

Not classified based on available information.

#### Product:

Acute oral toxicity	:	Acute toxicity estimate: > 2,000 mg/kg Method: Calculation method
Acute inhalation toxicity	:	Acute toxicity estimate: > 5 mg/l Exposure time: 4 h Test atmosphere: dust/mist Method: Calculation method

### **Components:**

### Emamectin:

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# **Emamectin Formulation**

Version 4.2	Revision Date: 28.09.2024	SDS Number: 24922-00029	Date of last issue: 06.04.2024 Date of first issue: 23.10.2014
Acute oral toxicity		Symptoms: I LD50 (Mous Symptoms: <sup>-</sup> TDLo (Rat):	76 - 78 mg/kg rritability, Salivation, Lachrymation, Tremors e): 22 - 31 mg/kg Tremors 0.5 - 25 mg/kg ns: Central nervous system, Peripheral nervous
Acute	e inhalation toxicity	system : LC50 (Rat, n Exposure tin	nale and female): > 0.663 - 1.049 mg/l
Acute	e dermal toxicity		> 2,000 mg/kg
		Target Organ	n: 500 - 1,000 mg/kg ns: Peripheral nervous system, Central nervous Fremors, Dilatation of the pupil
Skin	corrosion/irritation		

Not classified based on available information.

### Components:

#### Emamectin:

Species	:	Rabbit
Result	:	Mild skin irritation

### Serious eye damage/eye irritation

Not classified based on available information.

### Components:

#### Emamectin:

Species	:	Rabbit
Result	:	Irreversible effects on the eye

#### Respiratory or skin sensitisation

#### Skin sensitisation

Not classified based on available information.

#### Respiratory sensitisation

Not classified based on available information.

#### **Components:**

### Emamectin:

Test Type	:	Local lymph node assay (LLNA)
Exposure routes	:	Skin contact
Species	:	Mouse

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# **Emamectin Formulation**

Vers 4.2	sion	Revision Date: 28.09.2024		922-00029	Date of last issue: 06.04.2024 Date of first issue: 23.10.2014
	Assess Result	ment	:	Does not cause sl negative	kin sensitisation.
		<b>cell mutagenicity</b> ssified based on availa	able	information.	
	Compo	onents:			
	Emam	ectin:			
	Genoto	oxicity in vitro	:	Test Type: Bacter Result: negative	ial reverse mutation assay (AMES)
					mammalian cell gene mutation test ese hamster lung cells
					osomal aberration ese hamster ovary cells
				Test Type: Alkalin Test system: rat h Result: negative	
	Genoto	xicity in vivo	:	Test Type: in vivo Species: Mouse Cell type: Bone m Result: negative	
		ogenicity ssified based on availa	hle	information	
	-	onents:			
	Emam				
	Specie Applica			Mouse Oral 79 weeks 0.5 - 7.5 mg/kg bo negative	ody weight
		s ition Route ire time	:	Rat Oral 105 weeks 0.25 - 2.5 mg/kg b negative	oody weight

### **Reproductive toxicity**

Not classified based on available information.



# **Emamectin Formulation**

Version 4.2	Revision Date: 28.09.2024	SDS Number: 24922-00029	Date of last issue: 06.04.2024 Date of first issue: 23.10.2014
<u>Con</u>	ponents:		
Ema	mectin:		
Effe	cts on fertility	Species: Rat, n Application Rou General Toxicit Fertility: NOAE Early Embryoni weight	y - Parent: NOAEL: 0.6 mg/kg body weight L Parent: 0.6 mg/kg body weight c Development: LOAEL F1: 0.6 mg/kg body ect on reproduction capacity, Effects on fertility, ffspring
Effects on foetal develop- : ment		General Toxicit Developmental Result: No tera	t ute: Oral gle Treatment: 12 d y Maternal: NOAEL: 3 mg/kg body weight Toxicity: NOAEL F1: 6 mg/kg body weight togenic effects, Embryotoxic effects and ad- n the offspring were detected only at high ma-
		Developmental Result: No tera	ute: Oral gle Treatment: 13 d Toxicity: NOAEL F1: 4 mg/kg body weight togenic effects, Embryotoxic effects and ad- n the offspring were detected only at high ma-

### STOT - single exposure

Not classified based on available information.

### Components:

### Emamectin:

Exposure routes	:	Ingestion, Skin contact
Target Organs	:	Peripheral nervous system, Central nervous system
Assessment	:	Causes damage to organs.

### STOT - repeated exposure

Not classified based on available information.

### **Components:**

Emamectin:	
Target Organs Assessment	Peripheral nervous system, Central nervous system Causes damage to organs through prolonged or repeated exposure.

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



### **Emamectin Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
4.2	28.09.2024	24922-00029	Date of first issue: 23.10.2014

### **Repeated dose toxicity**

Components:	
Emamectin:Species:NOAEL:LOAEL:Application Route:Exposure time:Target Organs:	Rat 0.25 mg/kg 1 mg/kg Oral 105 Weeks Central nervous system
Species:NOAEL:LOAEL:Application Route:Exposure time:Target Organs:Symptoms:	Mouse 2.5 mg/kg 12.5 mg/kg Oral 79 Weeks Peripheral nervous system Tremors, Fatality
Species:NOAEL:LOAEL:Application Route:Exposure time:Target Organs:Symptoms:	Dog 0.25 mg/kg 0.5 mg/kg Oral 53 Weeks Peripheral nervous system, Central nervous system Tremors, Dilatation of the pupil

### Aspiration toxicity

Not classified based on available information.

### 11.2 Information on other hazards

#### **Endocrine disrupting properties**

#### Product:

Assessment

The substance/mixture does not contain components consid-: ered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

#### Experience with human exposure

#### Components:

Emamectin:	
Eye contact	: Symptoms: Severe irritation
	Remarks: Based on Animal Evidence
Ingestion	: Target Organs: Gastro-intestinal system
	Symptoms: Nausea, Vomiting, Abdominal pain, confusion



# **Emamectin Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
4.2	28.09.2024	24922-00029	Date of first issue: 23.10.2014

### **SECTION 12: Ecological information**

12.1	Toxicity				
	Components:				
	Emamectin:				
	Toxicity to fish	:	LC50 (Oncorhynchus mykiss (rainbow trout)): 0.174 mg/l Exposure time: 96 h		
			LC50 (Cyprinodon variegatus (sheepshead minnow)): 1.34 mg/l Exposure time: 96 h		
			LC50 (Lepomis macrochirus (Bluegill sunfish)): 0.18 mg/l Exposure time: 96 h		
	Toxicity to daphnia and other aquatic invertebrates	:	EC50 (Daphnia magna (Water flea)): 0.00099 mg/l Exposure time: 48 h		
			EC50 (Americamysis): 0.000043 mg/l Exposure time: 48 h		
	M-Factor (Acute aquatic tox- icity)	:	10,000		
	M-Factor (Chronic aquatic toxicity)	:	10,000		
12.2	Persistence and degradabilities No data available	ity			
12.3	Bioaccumulative potential				
	Components:				
	Emamectin:				
	Bioaccumulation	:	Species: Lepomis macrochirus (Bluegill sunfish) Bioconcentration factor (BCF): 80		
	Partition coefficient: n- octanol/water	:	log Pow: 5		
12.4	<b>Mobility in soil</b> No data available				
12.5	12.5 Results of PBT and vPvB assessment				
	Product: Assessment	:	This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.		



### **Emamectin Formulation**

Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
4.2	28.09.2024	24922-00029	Date of first issue: 23.10.2014

### **12.6 Endocrine disrupting properties**

### Product:

Assessment

: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

### 12.7 Other adverse effects

No data available

### **SECTION 13: Disposal considerations**

### 13.1 Waste treatment methods

Product	:	Dispose of in accordance with local regulations. According to the European Waste Catalogue, Waste Codes are not product specific, but application specific. Waste codes should be assigned by the user, preferably in discussion with the waste disposal authorities. Do not dispose of waste into sewer.
Contaminated packaging	:	Empty containers should be taken to an approved waste han- dling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

### **SECTION 14: Transport information**

14.1 UN number or ID number				
ADN	:	UN 3077		
ADR	:	UN 3077		
RID	:	UN 3077		
IMDG	:	UN 3077		
ΙΑΤΑ	:	UN 3077		
14.2 UN proper shipping name				
ADN	:	ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Emamectin)		
ADR	:	ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Emamectin)		
RID	:	ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S. (Emamectin)		
IMDG	:	ENVIRONMENTALLY HAZARDOUS SUBSTANCE, SOLID, N.O.S.		

according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878



# **Emamectin Formulation**

Version 4.2	Revision Date: 28.09.2024		S Number: 922-00029	Date of last issue: 06.04.2024 Date of first issue: 23.10.2014
			(Emamectin)	
IAI	ΓΑ	:	Environmentally h (Emamectin)	nazardous substance, solid, n.o.s.
14.3 Tra	ansport hazard class(es)			
			Class	Subsidiary risks
AD	N	:	9	
AD	R	:	9	
RI	0	:	9	
IM	DG	:	9	
IA	ГА	:	9	
14.4 Pa	cking group			
Cla Ha	N cking group assification Code zard Identification Number pels	: : :	III M7 90 9	
Cla Ha Lal	<b>PR</b> cking group assification Code zard Identification Number pels nnel restriction code	: : : : : : : : : : : : : : : : : : : :	III M7 90 9 (-)	
Cla Ha	<b>D</b> cking group assification Code zard Identification Number pels	: : :	III M7 90 9	
Pa Lal	DG cking group pels iS Code	:	III 9 F-A, S-F	
Pa	<b>FA (Cargo)</b> cking instruction (cargo craft)	:	956	
Pa Pa	cking instruction (LQ) cking group pels	: : :	Y956 III Miscellaneous	
Pa	<b>FA (Passenger)</b> cking instruction (passen- r aircraft)	:	956	
Pa Pa	cking instruction (LQ) cking group pels	::	Y956 III Miscellaneous	

### 14.5 Environmental hazards



according to Regulation (EC) No. 1907/2006, as amended by Commission Regulation (EU) 2020/878

# **Emamectin Formulation**

Version 4.2	Revision Date: 28.09.2024	SDS Number: 24922-00029	Date of last issue: 06.04.2024 Date of first issue: 23.10.2014
<b>ADN</b> Envir	onmentally hazardous	: ves	
ADR	-	. yes	
Envir	onmentally hazardous	: yes	
<b>RID</b> Envir	onmentally hazardous	: yes	
<b>IMDO</b> Marir	<b>G</b> ne pollutant	: yes	
	( <b>Passenger)</b> conmentally hazardous	: yes	
	( <b>Cargo)</b> conmentally hazardous	: yes	

### 14.6 Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

### 14.7 Maritime transport in bulk according to IMO instruments

Remarks : Not applicable for product as supplied.

### **SECTION 15: Regulatory information**

#### 15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

REACH - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, mixtures and articles (Annex XVII)	:	Not applicable	
REACH - Candidate List of Substances of Very High Concern for Authorisation (Article 59).	:	Not applicable	
Regulation (EC) on substances that deplete the ozone layer	:	Not applicable	
Regulation (EU) 2019/1021 on persistent organic pollu- tants (recast)	:	Not applicable	
Regulation (EU) No 649/2012 of the European Parlia- ment and the Council concerning the export and import of dangerous chemicals	:	Not applicable	
REACH - List of substances subject to authorisation (Annex XIV)	:	Not applicable	
Seveso III: Directive 2012/18/EU of the European Parlian major-accident hazards involving dangerous substances.		t and of the Counc	il on the control of
,		Quantity 1	Quantity 2

		Quantity 1	Quantity 2
E1	ENVIRONMENTAL	100 t	200 t
	HAZARDS		

# The components of this product are reported in the following inventories:AICS: not determined



# Emamectin Formulation

Version 4.2	Revision Date: 28.09.2024	-	DS Number: 1922-00029	Date of last issue: 06.04.2024 Date of first issue: 23.10.2014	
DSL		:	not determined		
IECS	SC	:	not determined		
<b>15.2 Chemical safety assessment</b> A Chemical Safety Assessment has not been carried out.					
SECTIO	N 16: Other informati	on			
Other information : Items where changes have been made to the previou are highlighted in the body of this document by two ve lines.					
Full	text of H-Statements				
H301 H318 H331 H370 H372	3   )		<ul> <li>Toxic if swallowed.</li> <li>Causes serious eye damage.</li> <li>Toxic if inhaled.</li> <li>Causes damage to organs if swallowed.</li> <li>Causes damage to organs through prolonged or repeated exposure.</li> </ul>		
H400 H410		:	Very toxic to aqua	atic life. atic life with long lasting effects.	
Full	text of other abbreviati	ons	i		
Aqua Aqua Eye I			<ul> <li>Acute toxicity</li> <li>Short-term (acute) aquatic hazard</li> <li>Long-term (chronic) aquatic hazard</li> <li>Serious eye damage</li> <li>Specific target organ toxicity - repeated exposure</li> <li>Specific target organ toxicity - single exposure</li> <li>Ireland. List of Chemical Agents and Carcinogens with Occupational Exposure Limit Values - Code of Practice, Schedule and 2</li> </ul>		
IE OI	EL / OELV - 8 hrs (TWA)	:		osure limit value (8-hour reference period)	
ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - Agreement concerning the International Carriage of Dangerous Goods by Road; AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Test-					

Waterways; ADR - Agreement concerning the International Carriage of Dangerous Goods by Road; AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA -European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL



### Emamectin Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 06.04.2024
4.2	28.09.2024	24922-00029	Date of first issue: 23.10.2014

- Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of Very High Concern; TCSI - Taiwan Chemical Substance Inventory; TECI -Thailand Existing Chemicals Inventory; TRGS - Technical Rule for Hazardous Substances; TSCA - Toxic Substances Control Act (United States); UN - United Nations; vPvB - Very Persistent and Very Bioaccumulative

#### Further information

data from raw material SDSs, OECD
esults and European Chemicals Agen-
eu/

Classification of the mixtur	Classification procedure:	
Aquatic Acute 1	H400	Calculation method
Aquatic Chronic 1	H410	Calculation method

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

IE / EN